Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Sareum Holdings PLC

SAR.L ✓ COMPLIANTFree checks used up today ☆ Track — members

LSE · Healthcare · Biotechnology & Medical Research ·

UK Micro Cap Analyst: BUY

Last Close

$0.36

▲ +0.00%

Market Cap $51.47M · Vol 126.55K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$51.47M

Micro Cap

Div Yield

N/A

Semi-annual dividend

EPS Growth

+7.34%

YoY

RSI (14)

0.00

Momentum

Beta

-0.03

vs Market

52W High

$0.54

33.12% below

52W Low

$0.16

132.27% above

Volume

126.55K

Avg 175.15K

P/B

9.44

Price-to-book

ROE

N/A

Return on equity

Free Float

96.28%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Sareum Holdings PLC (SAR.L) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does SAR.L pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+0.00%

-11.29%

+17.02%

+27.91%

YTD

+83.33%

+96.43%

-56.01%

-91.79%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-6,094,731.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-140.15% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	9.44
P/FCF	N/A
EPS Growth	+7.34%
Outstanding Shares	139.73M

Technical Indicators

50-Day SMA	$0.41
200-Day SMA	$0.30
RSI (14)	0.00
Beta	-0.03
52-Week High	$0.54
52-Week Low	$0.16

Volume Today	126.55K
Avg Daily Volume (30D)	175.15K
Relative Volume	0.72x
Volatility (10D)	0.00
Volatility (30D)	35.27
Free Float	96.28%

Analyst Consensus

BUY

Current Price $0.36

Mean Target $0.55

52W Low$0.16 52W High$0.54

Current

Target

$0.16 $0.54

Current Analyst target

+52.61% upside potential · 1 analysts

Identifiers

ExchangeLSE

FIGIBBG001SL3890

ISINGB00BMC3RJ87

CountryUK

Sub-IndustryBio Therapeutic Drugs

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. -6.02% ARGX.BR argenx SE -0.41% ARGX argenx SE -1.61% GMAB.CO Genmab A/S +1.30% GMAB Genmab A/S +1.09%

Company Profile

Sareum Holdings plc is a United Kingdom-based clinical-stage biotechnology company. The principal activity of the Company is the discovery and development of new therapeutic drugs using a combination of skills in biology, computational chemistry and medicinal chemistry. The Company is focused on advancing inhibitors of the JAK kinase family into clinical development for autoimmune disease and cancer. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases, including psoriasis, and has completed Phase 1 clinical development. The Company is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy. Additionally, the Company owns the license for SRA737, a clinical-stage oral, selective Checkpoint kinase 1 inhibitor that targets cancer cell replication and DNA damage repair mechanisms.